Keyphrases
Mucous Membrane Pemphigoid
100%
Ocular mucous Membrane Pemphigoid
66%
COVID-19 Pandemic
58%
Ocular Involvement
57%
Cardiovascular Effects
50%
Treatment-free Remission
50%
Clinical Characteristics
50%
Disease Relapse
50%
Access to Eye Care
50%
Evolving Roles
50%
Post-COVID-19 Condition
50%
Incidence Characteristics
50%
COVID-19
50%
Medicaid
50%
Healthcare Insurance
50%
Private Healthcare
50%
Interferon-gamma Autoantibody
50%
Echocardiography
50%
Extraocular
49%
Remission
42%
Blue Shield
35%
Blue Cross
35%
Hazard Ratio
34%
Confidence Interval
32%
Odds Ratio
30%
Cyclophosphamide
21%
Rituximab
21%
Echocardiographic Findings
20%
Optometrist
20%
Michigan
20%
Maryland
20%
Ophthalmologist
20%
Cardiovascular Manifestations
18%
Risk Factors
18%
Eye Care Professionals
15%
Eye Care
15%
Incidence Rate
14%
Relapse Risk
14%
Biopsy-proven
12%
Pericardial Effusion
10%
Prognostic Value
10%
Initial Infection
10%
Adverse Clinical Outcomes
10%
Cardiac Sequelae
10%
Insurance
10%
Caller
10%
Valvular Disease
10%
Waiting Time
10%
Triage
10%
Longitudinal Strain
10%
Nursing and Health Professions
Infection
71%
Interferon
50%
Autoantibodies
50%
Immune Deficiency
50%
Blood Vessel Injury
50%
Blue Cross Blue Shield
50%
Heart Failure
50%
Thrombosis
50%
Symptom
50%
Heart Arrhythmia
50%
Syndrome
50%
Health Service
50%
Pathophysiology
50%
Pandemic
50%
Severe Acute Respiratory Syndrome
50%
Patient Care
50%
Dysautonomia
50%
Cardiovascular Disease
50%
Heart Muscle Injury
50%
Eye Care
50%
Odds Ratio
42%
Optometrist
28%
Ophthalmologist
28%
Eye Care Professional
21%
Eye Examination
14%
Skin Infection
7%
Rituximab
7%
Cyclophosphamide
7%
Disease Course
7%
Persistent Infection
7%
Autoimmune Disease
7%
Clinical Feature
7%
National Health Organization
7%
Health Outcomes
7%
Diabetes Mellitus
7%
Low Income Population
7%
Confounding Factor
7%
Vision Care
7%
Prospective Cohort Study
7%
Vision Test
7%
Medicine and Dentistry
Cicatricial Pemphigoid
100%
Disease
58%
COVID-19
58%
Immune Deficiency
50%
Interferon
50%
Autoantibodies
50%
Echocardiography
50%
Post-COVID-19
50%
Cardiovascular Effect
50%
Infection
38%
Rituximab
27%
Hazard Ratio
24%
Cyclophosphamide
22%
Cardiovascular System
16%
Symptom
16%
Biological Marker
16%
Biopsy
9%
Heart Muscle Injury
8%
Pericardial Fluid
8%
Patient Care
8%
Organ Systems
8%
Cardiovascular Disease
8%
Dysautonomia
8%
Heart Left Ventricle Failure
8%
Pathophysiology
8%
Speckle Tracking Echocardiography
8%
Cardiac Dysrhythmia
8%
Heart Failure
8%
Sequela
8%
Blood Vessel Injury
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Thrombosis
8%
Clinical Feature
7%
Mycobacterium Avium Complex
7%
Persistent Infection
7%
Mycobacterium abscessus
7%
Skin Infection
7%
Atypical Mycobacterium
7%
Central Nervous System
7%
Lung
7%
Disease Course
7%
Autoimmune Disease
7%
Systemic Therapy
5%
Eye Disease
5%
Immunosuppressive Drug
5%
Recurrence Risk
5%
Patient Monitoring
5%
